Back to search

Article

Potent antitumor activity of a designed interleukin-21 mimic

2024-12-07

Abstract excerpt

Long-standing goals of cancer immunotherapy are to activate cytotoxic antitumor T cells across a broad range of affinities while dampening suppressive regulatory T (Treg) cell responses, but current approaches achieve these goals with limited success. Here, we report a de novo IL-21 mimic, 21h10, designed to have augmented stability and high signaling potency in both humans and mice. In multiple animal models and...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
174569e4-2cc3-5055-bd22-d8dd02de6863
DOI
10.1101/2024.12.06.626481
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Potent antitumor activity of a designed interleukin-21 mimicDOI 10.1101/2024.12.06.626481
An engineered IL-21 variant is a potent antitumor candidate for antitumor immunotherapy.Semantic proximity
Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protectionSemantic proximity
Rational design of immune gene therapy combinations via <i>in vivo</i> CRISPR activation screen of tumor microenvironment modulatorsSemantic proximity
Engineering immunoproteasome-expressing mesenchymal stromal cells: A potent cellular vaccine for lymphoma and melanoma in mice.Semantic proximity
The antitumor effect induced by an IL-2 'no-alpha' mutein depends on changes in the CD8+ T lymphocyte/Treg cell balance.Semantic proximity
An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organismSemantic proximity
Multiparameter comparative analysis reveals differential impacts of various cytokines on CART cell phenotype and function ex vivo and in vivo.Semantic proximity
The antibody-based delivery of interleukin-12 to solid tumors boosts NK and CD8 <sup>+</sup> T cell activity and synergizes with immune check-point inhibitorsSemantic proximity
IL-21 promotes the expansion of CD27+ CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells.Semantic proximity
Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC).Semantic proximity
Efficacy of Anti-Cancer Immune Responses Elicited Using Tumor-Targeted IL-2 Cytokine and Its Derivatives in Combined Preclinical TherapiesSemantic proximity
Pooled screening of CAR T cells identifies non-native signaling domains for next-generation immunotherapiesSemantic proximity
Select a neighboring publication to make it the new centre.